DexCom, Inc. logo


DexCom, Inc.


Earnings Summary

Net Profits
Net Profit Margins



DexCom, Inc.’s revenue jumped 24.51% since last year same period to $628.8Mn in the Q1 2022. On a quarterly growth basis, DexCom, Inc. has generated -9.94% fall in its revenue since last 3-months.

Net Profits:

DexCom, Inc.’s net profit jumped 141.44% since last year same period to $97.3Mn in the Q1 2022. On a quarterly growth basis, DexCom, Inc. has generated 601.55% jump in its net profits since last 3-months.

Net Profit Margins:

DexCom, Inc.’s net profit margin jumped 93.9% since last year same period to 15.47% in the Q1 2022. On a quarterly growth basis, DexCom, Inc. has generated 656.9% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the DexCom, Inc. post its latest quarter earnings

EPS Estimate Current Quarter
EPS Estimate Current Year


EPS Estimate Current Quarter:

DexCom, Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.27 - a 12.5% jump from last quarter’s estimates.

EPS Estimate Current Year:

DexCom, Inc.’s earning per share (EPS) estimates for the current year stand at 0.27.

Key Ratios

Key ratios of the DexCom, Inc. post its Q3 2022 earnings

Earning Per Share (EPS)
Return on Assets (ROA)
Return on Equity (ROE)


Earning Per Share (EPS):

DexCom, Inc.’s earning per share (EPS) jumped 27.27% since last year same period to 0.28 in the Q3 2022. This indicates that the DexCom, Inc. has generated 27.27% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. DexCom, Inc.’s return on assets (ROA) stands at 0.04.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. DexCom, Inc.’s return on equity (ROE) stands at 0.09.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %

Company Information

DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) products. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of patients, caregivers, and clinicians, Dexcom simplifies and improves diabetes management around the world.

DexCom, Inc.
6340 Sequence Drive, San Diego, CA, United States, 92121
Health Technology
Kevin Sayer

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*